Aug 7 2015
BioteQ Environmental Technologies Inc., a leader in the treatment of mine waters, has secured a contract with a Canadian mining company to complete a pilot scale demonstration and evaluation of its Selen-IX™ technology to remove selenium from mine impacted water to less than 1 part per billion.
The project will utilize BioteQ's existing mobile Selen-IX™ pilot plant and the scope of work and associated contract value are similar to recently completed pilot projects using the same Selen-IX™ mobile unit. BioteQ has commenced mobilization of its plant and is expected to complete piloting in Q4 2015.
David Kratochvil, President & Chief Executive Officer at BioteQ commented, "This new pilot contract demonstrates the increasing focus on controlling selenium by mining companies, regulators and impacted communities. Selen-IX™ can help address these issues by removing selenium to ultra-low levels compliant with the most stringent regulations in the world, and produce significant life cycle cost savings compared to existing solutions particularly when the treatment horizon is greater than 10 years."
BioteQ Corporate Profile
BioteQ is a service provider that specializes in treating mining wastewater and specific hydrometallurgical streams with the focus on reducing Life Cycle Costs while achieving compliance and introducing sustainability into water management. We have extensive expertise and operations experience in sulphide precipitation, ion exchange, alkali/lime neutralization and SART process technologies. Over the past decade, BioteQ has designed and commissioned plants at mine sites for leading organizations including Glencore Canada, Freeport McMoRan, Jiangxi Copper and the US EPA and is currently operating six plants under long-term contracts. These plants remove dissolved metals and sulphate to well below the required regulatory discharge limits while reducing or eliminating the production of waste sludge and/or recovering valuable metals from waste streams for sale which reduces the life cycle cost of water treatment. BioteQ is headquartered in Vancouver, Canada and trades on the TSX under the symbol BQE. Please visit our website at www.bioteq.ca for additional information.
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.
Source: http://www.bioteq.ca/